Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

• Status: Recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mirati Therapeutics Inc.
• Treatments: Adagrasib; Afatinib; Cetuximab; Pembrolizumab

Criteria

Inclusion Criteria:

• Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation

• Unresectable or metastatic disease

• Standard treatment is not available or patient declines; first-line treatment for NSCLC for certain cohorts

• Adequate organ function

Exclusion Criteria:

• History of intestinal disease or major gastric surgery or inability to swallow oral medications

• Other active cancer